SMAD3 and Alzheimer disease: Validation of the VEGFA-SMAD3 ligand-target pair interactions using in vitro and in vivo model systems pave the way to uncover mechanistic interactions between pericytes, endothelia, and astrocytes and their perturbations in AD.